01.02.2024 - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference: .
Acadia Pharmaceuticals Inc. today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and.
South Dakota Investment Council decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.9% during the 3rd quarter, Holdings Channel reports. The firm owned 183,758 shares of the biotechnology company’s stock after selling 3,500 shares during the quarter. South Dakota Investment Council’s holdings in Exelixis were worth $4,015,000 at the end of the […]
Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective upped by analysts at Barclays from $24.00 to $25.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target points to a potential upside of 14.21% from the stock’s current price. […]
Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective boosted by research analysts at Barclays from $24.00 to $25.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 14.21% from the stock’s […]